Faculty Disclosures
			
				|  | No disclosure on file | 
			
				| Stewart A. Factor, DO, FAAN | Dr. Factor has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Factor has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Factor has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda.  The institution of Dr. Factor has received research support from Biohaven.  The institution of Dr. Factor has received research support from Neurocrine.  The institution of Dr. Factor has received research support from Supernus.  The institution of Dr. Factor has received research support from  Sun Pharmaceuticals Advanced Research Company.  The institution of Dr. Factor has received research support from Aspen.  The institution of Dr. Factor has received research support from RHO. Dr. Factor has received publishing royalties from a publication relating to health care. Dr. Factor has received publishing royalties from a publication relating to health care. Dr. Factor has received publishing royalties from a publication relating to health care. Dr. Factor has received publishing royalties from a publication relating to health care. | 
			
				| Jacqueline French, MD, FAAN | Dr. French has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Epilepsy Foundation.  The institution of Dr. French has received research support from Epilepsy Study Consortium/ Epilepsy Foundation (Funded by UCB).  The institution of Dr. French has received research support from GW/One8 Foundation/FACES.  The institution of Dr. French has received research support from NINDS.  The institution of Dr. French has received research support from Xenon.  The institution of Dr. French has received research support from Cerevel.  The institution of Dr. French has received research support from FACES.  The institution of Dr. French has received research support from UCB.  The institution of Dr. French has received research support from Epilepsy Study Consortium.  The institution of Dr. French has received research support from UCB.  The institution of Dr. French has received research support from Praxis. Dr. French has received personal compensation in the range of $50,000-$99,999 for serving as a Chief Medical/Innovation Officer with Epilepsy Foundation. Dr. French has a non-compensated relationship as a Consultant with Acadia Pharmaceuticals Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Access Industries that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Acuta Capital Partners LLC that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with AFASCI Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Agrithera, Inc. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Alkermes  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Alterity Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Angelini Pharma S.p.A. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Autifony Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Axonis Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Bain Capital that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Beacon Biosciences that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Biogen that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Biohaven Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Bloom Science, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Bright Minds Biosciences, Inc. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Capsidia Biotherapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Cerebral Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cerecin, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Cerevel that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, SAB with Cognizance Biomarkers that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Ceribell that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cowen that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Crossject that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory Board  with EcoR1 Capital that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with EG 427 that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant, Advisory Board  with Eisai that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Encoded Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant/Advisory Board  with Engrail that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Epitel, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with EpiMinder that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Grin Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Harmony that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory Board  with Ionis Pharmaceutical  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with iQure Pharma, Inc  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with IQVIA that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Janssen Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Jazz Pharmaceutical  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Leal Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, with Livanova  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with London Research & Pharmaceuticals  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Longboard Pharmaceutical  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Maplight Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Marinus  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Medscape/Web MD  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Modulight Bio that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Montara Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Mosaica Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Neumarker that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Neumirna Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Neurelis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consulting, Advisory Board  with Neurocrine  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Neuropace  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with NeuroPro Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Neuroventis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting  with Neurona Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, Advisory Board  with Neuvarti  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Noema  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Ono Pharmaceutical  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, Advisory Board  with Otsuka  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consulting, Advisory Board  with Ovid Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Praxis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with PureTech LYT Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with QurAlis Corp that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Rapport Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Receptor Holdings, Inc  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Rivervest Venture Partners  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Sage Therapeutics, Inc  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with SK Life Science  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Stoke  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Stream Neuroscience  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Supernus that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Takeda  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Taysha Gene Therapies  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with UCB, Inc  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with uniQure  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Ventus Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Vida Ventures Management  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Xenon Pharmaceuticals  that is relevant to AAN interests or activities. | 
			
				| Robert A. Hauser, MD, MBA, FAAN | Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kyowa Kirin Pharmaceuticals. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine Biosciences. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NeuroDerm. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Revance Therapeutics. Dr. Hauser has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Supernus Pharma. Dr. Hauser has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Abbvie. Dr. Hauser has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Amneal. Dr. Hauser has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Regenxbio. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Forsee Pharmaceuticals. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for KiefeRx. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Intrance. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zambon. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Truebinding. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Serina Therapeutics. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nano PharmaSolutions. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HanAll. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sorridi Therapeutics. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Conterra Pharma. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Clario. Dr. Hauser has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Theravance. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Photopharmics. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cerevance. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NDP Pharmaceuticals. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoparkinson. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Inhibikase.  The institution of Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoparkinson.  The institution of Dr. Hauser has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Photopharmics. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amneal . Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Hauser has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Neurocrine Biosciences. Dr. Hauser has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Supernus. Dr. Hauser has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Abbvie. Dr. Hauser has stock in Inhibikase. Dr. Hauser has stock in Axial Therapeutics. Dr. Hauser has stock in Enterin.  The institution of Dr. Hauser has received research support from Annovis Bio, Inc..  The institution of Dr. Hauser has received research support from Inhibikase Therapeutics.  The institution of Dr. Hauser has received research support from AbbVie, Inc..  The institution of Dr. Hauser has received research support from Biogen MA.  The institution of Dr. Hauser has received research support from Cavion, Inc..  The institution of Dr. Hauser has received research support from Cerevance Beta, Inc..  The institution of Dr. Hauser has received research support from Cerevel Therapeutics.  The institution of Dr. Hauser has received research support from Enterin, Inc..  The institution of Dr. Hauser has received research support from Genentech.  The institution of Dr. Hauser has received research support from Global Kinetics Corporation.  The institution of Dr. Hauser has received research support from Hoffman-La Roche Inc.  The institution of Dr. Hauser has received research support from Michael J. Fox Foundation for Parkinson's Research.  The institution of Dr. Hauser has received research support from National Parkinson's Foundation.  The institution of Dr. Hauser has received research support from Neuroderm.  The institution of Dr. Hauser has received research support from Sage Therapeutics.  The institution of Dr. Hauser has received research support from Scion NeuroStim.  The institution of Dr. Hauser has received research support from UCB BioPharma.  The institution of Dr. Hauser has received research support from UCB.  The institution of Dr. Hauser has received research support from Amneal Pharmaceuticals.  The institution of Dr. Hauser has received research support from Motric Bio, Inc..  The institution of Dr. Hauser has received research support from Sun Pharma Advanced Research Company.  The institution of Dr. Hauser has received research support from Teva Branded Pharmaceuticals.  The institution of Dr. Hauser has received research support from Truebinding, Inc.. Dr. Hauser has received intellectual property interests from a discovery or technology relating to health care. | 
			
				| Joseph Jankovic, MD, FAAN | Dr. Jankovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Revance. Dr. Jankovic has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance, Allergan.  The institution of Dr. Jankovic has received research support from Baylor College of Medicine. Dr. Jankovic has received research support from Abbvie.  The institution of Dr. Jankovic has received research support from Abbvie. | 
			
				| Walter J. Koroshetz, MD, FAAN | Dr. Koroshetz has nothing to disclose. | 
			
				| Anthony E. Lang, MD, FAAN | Dr. Lang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AbbVie, Amylyx, Aprinoia, Biogen, BioAdvance, Biohaven, BioVie, BlueRock, BMS, Denali, Janssen, Lilly, Pharma 2B, Sun Pharma, and UCB. Dr. Lang has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for medicolegal cases related to paraquat.  The institution of Dr. Lang has received research support from AbbVie. Dr. Lang has received intellectual property interests from a discovery or technology relating to health care. Dr. Lang has received publishing royalties from a publication relating to health care. | 
			
				| Paul A. Nausieda, MD, FAAN | No disclosure on file | 
			
				| C. W. Olanow, MD | Dr. Olanow has received personal compensation for serving as an employee of Clintrex Research Corporation. Dr. Olanow has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Clintrex Research Corporation. Dr. Olanow has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Chevron/Syngenta. Dr. Olanow has stock in Clintrex Research Corporation. | 
			
				| Walter A. Rocca, MD, MPH | The institution of Dr. Rocca has received research support from National Institute on Aging - NIH.  The institution of Dr. Rocca has received research support from National Heart, Lung, and Blood Institute - NIH. | 
			
				| Mark Stacy, MD | Dr. Stacy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biovie. Dr. Stacy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for National Institute of Aging. Dr. Stacy has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Dartmouth. Dr. Stacy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement Disorders Journal. | 
			
				| Gregory Krauss, MD | Dr. Krauss has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arvelle. Dr. Krauss has received stock or an ownership interest from EpiWatch. | 
			
				| Rajesh Pahwa, MD, FAAN | Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbott. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ACADIA. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amneal. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Insightec. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jaaz. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fasikl. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genetech. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Photopharmics.  The institution of Dr. Pahwa has received research support from Abbott.  The institution of Dr. Pahwa has received research support from Abbvie.  The institution of Dr. Pahwa has received research support from Biogen.  The institution of Dr. Pahwa has received research support from Parkinson Foundation.  The institution of Dr. Pahwa has received research support from Roche.  The institution of Dr. Pahwa has received research support from Sage.  The institution of Dr. Pahwa has received research support from Sun Pharma.  The institution of Dr. Pahwa has received research support from Theravance.  The institution of Dr. Pahwa has received research support from Neuroderm.  The institution of Dr. Pahwa has received research support from Ask Bio.  The institution of Dr. Pahwa has received research support from Blue Rock.  The institution of Dr. Pahwa has received research support from Cerevance.  The institution of Dr. Pahwa has received research support from Fasikl.  The institution of Dr. Pahwa has received research support from Scion.  The institution of Dr. Pahwa has received research support from UCB.  The institution of Dr. Pahwa has received research support from Ono.  The institution of Dr. Pahwa has received research support from Intra-cellular Therapies.  The institution of Dr. Pahwa has received research support from Ask Bio.  The institution of Dr. Pahwa has received research support from Michael J Fox Foundation .  The institution of Dr. Pahwa has received research support from Neuron 23.  The institution of Dr. Pahwa has received research support from Roche. | 
			
				| Joao O. Siffert, MD | No disclosure on file | 
			
				| Alfredo Thomson, MD | Dr. Thomson has nothing to disclose. | 
			
				| Michele Tagliati, MD, FAAN | Dr. Tagliati has received publishing royalties from a publication relating to health care. | 
			
				| Olivier F. Gout, MD | Dr. Gout has nothing to disclose. | 
			
				| Andres M. Lozano, MD | Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbott. Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Insightec. Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Functional Neuromodulation. | 
			
				| Aaron Ellenbogen, DO | Dr. Ellenbogen has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for allergan. Dr. Ellenbogen has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for allergan. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Supernus. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for ipsen. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acorda. | 
			
				| Bjorn E. Oskarsson, MD, FAAN | Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx.  The institution of Dr. Oskarsson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for  Biogen. Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AnnJi.  The institution of Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for  Mitsubishi. Dr. Oskarsson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Tsumura.  The institution of Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MediciNova.  The institution of Dr. Oskarsson has received research support from  Biogen.  The institution of Dr. Oskarsson has received research support from Medicinova.  The institution of Dr. Oskarsson has received research support from Cytokinetics.  The institution of Dr. Oskarsson has received research support from Calico.  The institution of Dr. Oskarsson has received research support from  Mitsubishi.  The institution of Dr. Oskarsson has received research support from Tsumura.  The institution of Dr. Oskarsson has received research support from Sanofi.  The institution of Dr. Oskarsson has received research support from AZTherapeutics.  The institution of Dr. Oskarsson has received research support from Orion.  The institution of Dr. Oskarsson has received research support from Esaii. | 
			
				| Ann F. Hsu, PhD, PharmD | No disclosure on file | 
			
				| Raymond Bartus, PhD | No disclosure on file | 
			
				| John Petkau, PhD | No disclosure on file | 
			
				| Jeffrey M. Gelfand, MD, MS, FAAN | Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio.  An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain.  The institution of Dr. Gelfand has received research support from Genentech/Roche.  The institution of Dr. Gelfand has received research support from Vigil Neurosciences.  An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities. | 
			
				| Suneel K. Gupta, PhD | No disclosure on file |